BIOSTAXPAR Stock

BTAX

US45252A3059

Delayed OTC Markets Other stock markets 17:02:59 18/05/2026 +03			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

03-27	Callan Jmb Inc. Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2B/3 Advancement in A Collaboration Led by Difgen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp and Sgp Holdings	CI
03-25	DifGen Pharmaceuticals and Aveva Drug Delivery Systems Form Strategic Platform Collaboration with Biostax Corp D/B/A Attune Biotech, SGP Holdings, and Callan JMB	CI

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Market Cap	1.34M 1.15M 1.06M 996K 1.87M 126M 1.89M 12.55M 4.9M 61.93M 5.02M 4.92M 214M	P/E Ratio 2022	-6x	P/E Ratio 2023	-3.65x
Enterprise Value	2.49M 2.15M 1.98M 1.85M 3.48M 236M 3.52M 23.37M 9.13M 115M 9.35M 9.15M 399M	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	-	Yield 2022 *	-	Yield 2023	-

03-27	Callan Jmb Inc. Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2B/3 Advancement in A Collaboration Led by Difgen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp and Sgp Holdings	CI
03-25	DifGen Pharmaceuticals and Aveva Drug Delivery Systems Form Strategic Platform Collaboration with Biostax Corp D/B/A Attune Biotech, SGP Holdings, and Callan JMB	CI
01-15	Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune	CI
12-22	Biostax Corp. announced that it expects to receive $7.453728 million in funding	CI
11/04/25	Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
19/08/24	Biostax Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
05/07/24	Biostax Corp. Auditor Raises 'Going Concern' Doubt	CI
20/05/24	Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04/24	Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/11/23	Biostax Corp. Appoints Craig Suro as a Director	CI
14/11/23	Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
02/11/23	Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors	CI
05/10/23	Immune Therapeutics, Inc. will Change its Name to Biostax Corp	CI

21/02/25	Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration	AQ
30/11/23	Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception	AQ
15/11/23	Biostax Announces a Director Appointment of Influential Business Leader Craig Suro	AQ
02/11/23	Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors	AQ
24/10/23	Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment	AQ

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.9
5 years	0		6
10 years	0		186

Manager	Title	Age	Since
Kelly Wilson CEO	Chief Executive Officer	55	03/11/2022
Noreen Griffin CEO	Chief Executive Officer	73	01/03/2012
Glen Farmer DFI	Director of Finance/CFO	57	02/08/2022

BIOSTAXPAR Stock

Stocks

BTAX

US45252A3059

Valuation: BIOSTAXPAR

Chart: BIOSTAXPAR

Latest news : BIOSTAXPAR

Press Releases: BIOSTAXPAR

Course Extremes

Managers and Directors: BIOSTAXPAR

Latest insider transactions

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Robert Wilson BRD	Director/Board Member	53	31/05/2022
Mary Caperton BRD	Director/Board Member	64	24/10/2023
Roger Suro BRD	Director/Board Member	52	08/11/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/02/23	Glen Farmer	Buy	Chief Financial Officer	409,000	0.4925%
25/07/22	Kelly Wilson	Other	Chief Operating Officer	19,307,145	3,991.4381%
28/05/21	Raster Investments, Inc.	Other	Company	25,650	5.3226%

	2022	2023
Net sales	-	-
Net income	-3.54M -3.05M -2.8M -2.63M -4.94M -334M -4.99M -33.16M -12.95M -164M -13.27M -12.99M -566M	-1.65M -1.42M -1.31M -1.23M -2.31M -156M -2.33M -15.48M -6.05M -76.39M -6.19M -6.06M -264M
Net Debt	546K 471K 433K 406K 763K 51.6M 771K 5.12M 2M 25.27M 2.05M 2.01M 87.44M	1.15M 995K 916K 859K 1.61M 109M 1.63M 10.82M 4.23M 53.42M 4.33M 4.24M 185M